Core Viewpoint - The innovative pharmaceutical stocks have shown significant gains, driven by the upcoming 44th JPMorgan Healthcare Conference, where multiple Chinese innovative drug companies are set to participate [1] Group 1: Stock Performance - Innovent Biologics (01530) increased by 6.35%, trading at HKD 28.82 [1] - WuXi AppTec (02359) rose by 7.22%, trading at HKD 118.8 [1] - Lepu Biopharma-B (02157) saw a rise of 6.64%, trading at HKD 28.9 [1] - Galenica-B (01672) increased by 4.09%, trading at HKD 12.97 [1] - Genscript Biotech (01952) rose by 3.97%, trading at HKD 40.84 [1] Group 2: Conference Participation - The 44th JPMorgan Healthcare Conference is set to begin on January 12, 2026, in San Francisco, with several Chinese innovative drug companies confirming their attendance [1] - Key speakers include WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary, along with innovative drug companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech [1] - A total of 17 companies, including Hengrui Medicine, Baillie Gifford, Innovent Biologics, and Rongchang Biologics, will participate in the Asia-Pacific session [1] Group 3: Industry Insights - According to Guojin Securities, the conference serves as a critical platform for domestic pharmaceutical companies to showcase their core molecular product capabilities and advance overseas business development collaborations [1] - The industry is transitioning back to a phase of global value verification for products, with ongoing clinical advancements, significant data releases, and improved competitive dynamics driving multiple rounds of revaluation for product global value and corporate valuations [1] - Huayuan Securities indicates that the Chinese pharmaceutical industry has largely completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth trajectories for companies [1]

300ESGETF华夏（159791）业绩比较基准为沪深300ESG基准指数收益率，管理人为华夏基金管理有限 公司，基金经理为张金志，成立（2022-02-24）以来回报为13.17%，近一个月回报为4.46%。 来源：新浪基金∞工作室 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月13日，300ESGETF华夏（159791）开盘涨0.00%，报1.129元。300ESGETF华夏（159791）重仓股方 面，宁德时代开盘涨1.26%，贵州茅台涨0.25%，招商银行涨0.19%，中际旭创跌1.89%，长江电力涨 0.18%，美的集团跌0.92%，比亚迪涨1.57%，兴业银行涨0.10%，工商银行涨0.13%，恒瑞医药涨 0.70%。 ...

Core Insights - The report emphasizes the importance of long-term investment strategies and the need for a conducive regulatory environment to attract more long-term capital into the market [5] - It highlights the expected increase in storage prices by 40%-50% in Q1 2026, indicating potential investment opportunities in related companies [6] - The report notes a surge in approvals for innovative domestic drugs, presenting a favorable environment for pharmaceutical companies [6] Domestic Financial Market - The Shanghai Composite Index closed at 4165.29, up by 1.09%, while the Shenzhen Component Index rose by 1.75% to 14366.91 [3] - The ChiNext Index increased by 1.82%, closing at 3388.34, reflecting a positive market sentiment [3] Macro News Summary - The China Securities Regulatory Commission (CSRC) aims to enhance the institutional environment for long-term investments [5] - The National Bureau of Statistics is exploring innovative registration systems to unlock data value [5] - The Ministry of Industry and Information Technology is focusing on advanced technologies such as quantum technology and 6G during the 14th Five-Year Plan [5] Industry Developments - Storage prices are projected to rise significantly, with companies like Lanke Technology and Changdian Technology being highlighted as potential beneficiaries [6] - Meta's investment in a nuclear power plant for AI power supply suggests growth in the nuclear fusion industry, with companies like Lianchuang Optoelectronics and China Nuclear Engineering being relevant [6] - The approval of innovative drugs is expected to create opportunities for companies like BeiGene and Heng Rui Medicine [6] Company Focus - Kexiang Co., Ltd. is noted for its PCB products used in aerospace and storage devices [7] - East China Pharmaceutical's subsidiary has developed a breakthrough treatment for severe hypertriglyceridemia [7] - Yinkang Life has established a comprehensive management solution for Parkinson's disease treatment [7] - Shengyang Technology is recognized as the sole provider of DVB-NIP software and hardware, gaining recognition from a leading European satellite operator [7] Market Review and Outlook - The market experienced a strong upward trend with all major indices closing higher, and trading volume exceeding 3.6 trillion yuan [8] - Sectors such as software services, internet, and aerospace saw significant gains, driven by AI-related catalysts [8] - Precious metals like gold and silver reached historical highs, indicating a shift in investor sentiment [8] - The report suggests a continued positive outlook for industrial resource sectors and low-positioned stocks benefiting from policy changes [9]

Policy Trends - The National Medical Insurance Administration has intensified anti-corruption efforts in the medical sector, highlighted by a case involving a doctor who accepted kickbacks totaling 789,100 yuan from pharmaceutical companies between 2012 and 2023 [1] - The Central Commission for Discipline Inspection has emphasized the need to address issues such as "kickback sales" and has included them in the scope of strict investigation [1] Drug Approval - Hualan Biological announced that its subsidiary received a notice of acceptance for the domestic production registration application of Adalimumab injection, a biosimilar drug for treating various immune diseases [1] - China Resources Double Crane's subsidiary has received implied permission from the FDA for clinical trials of the new drug DC6001 [2] - Heng Rui Medicine's SHR-1826 injection has been included in the list of breakthrough therapy varieties by the National Medical Products Administration [3] Financial Disclosures - WuXi AppTec expects a net profit of 19.151 billion yuan for 2025, representing a year-on-year increase of approximately 102.65% [4] - Sharp Eye's projected net profit for 2025 is expected to be negative due to anticipated goodwill impairment [5] Industry Developments - Haixiang Pharmaceutical has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical to develop treatments for amyotrophic lateral sclerosis, with Haixiang providing 150 million yuan in funding [6] - Innovation Medical's product, Cyberlink AC5, was officially launched in October 2025, generating revenue of 114,000 yuan, while the AM5 product has completed clinical trials but has not yet generated revenue [6] Regulatory Actions - The National Medical Products Administration has initiated an investigation into Anhui Telunshake Biotechnology for violations of cosmetic production regulations, leading to a halt in production and a requirement for corrective actions [7]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS-7535, a novel oral small molecule GLP-1 receptor agonist aimed at treating hypertension combined with overweight or obesity [1] Group 1: Drug Development - HRS-7535 is designed to activate GLP-1 receptors to regulate insulin and glucagon secretion, inhibit gastric emptying, and enhance satiety while suppressing appetite through central mechanisms [1] - The drug is the first oral small molecule GLP-1 receptor agonist to be developed globally, indicating a potential market opportunity [1] Group 2: Financial Investment - Approximately 369.4 million RMB has been invested in the research and development of HRS-7535 to date [1] Group 3: Regulatory Process - Following the approval for clinical trials, the drug must complete clinical testing and receive further review and approval from the National Medical Products Administration before it can be marketed, highlighting the uncertainties in the development and commercialization process [1]

Group 1 - Jiangsu Hengrui Medicine Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for clinical trials of HRS-7535 tablets, which are intended for the treatment of hypertension combined with overweight or obesity [1][2] - HRS-7535 is a novel oral small molecule GLP-1 receptor agonist that promotes insulin secretion and reduces glucagon secretion, while also enhancing satiety and suppressing appetite, making it suitable for treating type 2 diabetes and weight loss [2] - The total R&D investment for HRS-7535 has reached approximately 36.94 million yuan [2] Group 2 - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapy drugs by the NMPA [5][6] - SHR-1826 is a therapeutic biological product targeting c-Met, intended for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have failed at least one line of systemic therapy [6][7] - The total R&D investment for SHR-1826 has reached approximately 12.55 million yuan [7]

剑桥科技(06166)控股子公司通过高新技术企业认定 智谱(02513)回应与出行平台合作不涉内幕消息 业务推进属日常范畴 重大事项： 红星冷链(01641)：香港公开发售获2309.25倍认购 每股发售价12.26港元 BBSB INTL(08610)：公开发售获10745.13倍认购 每股发售价0.6港元 兆易创新(03986)香港公开发售获542.22倍认购 全球发售净筹约46.11亿港元 恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单 百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗 体双药物偶联物项目 东风集团股份(00489)2025年度累计汽车销量为189.62万辆 同比增长约0.01% 中银航空租赁(02588)2025年全年自有飞机利用率保持在100% 龙湖集团(00960)2025年度累计实现总合同销售金额631.6亿元 中国软件国际(00354)投资企业MiniMax(00100)港交所上市 全栈AI战略版图再拓新篇 达力普控股(01921)拟300万沙特里亚尔出售达力普国际40%股权 引入沙特战略投资者推 ...

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration [1] Group 1: Product Information - SHR-1826 is an antibody-drug conjugate targeting c-Met, designed to specifically bind to tumor cell surface antigens and induce cell death upon internalization [1] - A similar product, ABBV-399 (generic name: telisotuzumab vedotin), received accelerated approval from the FDA in May 2025 for treating adult patients with advanced/metastatic non-squamous non-small cell lung cancer who have previously undergone systemic therapy and exhibit high expression of c-Met protein [1] Group 2: Financial Investment - The cumulative research and development investment related to SHR-1826 has reached approximately 125.5 million yuan [1]

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS-7535, a novel oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1] Group 1: Product Development - HRS-7535 is designed to activate GLP-1 receptors, promoting insulin secretion from the pancreas, reducing glucagon secretion, and suppressing gastric emptying [1] - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to reduced energy intake [1] - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1] Group 2: Financial Investment - The cumulative research and development investment for HRS-7535 has reached approximately 369.4 million yuan [1]

Group 1 - Core viewpoint: Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Suzhou Hengrui Medicine Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] - Drug name: Injectable SHR-1826, with acceptance number CXSL2300466, classified as a Class 1 therapeutic biological product [1] - Proposed indication: Monotherapy for locally advanced or metastatic non-squamous non-small cell lung cancer with c-Met overexpression (2-3+, ≥50%) in patients who have failed at least one line of systemic treatment [1] Group 2 - Application date: December 1, 2025, for the registration of SHR-1826 [1] - Reason for inclusion: The application meets the requirements of the "Drug Registration Management Measures" and the announcement regarding the "Breakthrough Therapeutic Drug Review Procedures" [1]